Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol “SPRB” and CUSIP 85209E 208.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250915439985/en/

Spruce Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
[email protected]
[email protected]

Spruce Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
[email protected]

Source: Spruce Biosciences, Inc.

You May Also Be Interested In

• Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI
• Why Is SHIB Up 5% Today? Bullish Meme Market Trends Point Toward This Upcoming Meme Coin Presale 
• Spruce Biosciences BLA filing for rare disease drug on track for 2026